BCR and B-cell chronic lymphocytic leukemia: This is partially conterintuitive since the acute effect of ibrutinib is a reduction in pAktS473 levels (see Figure 1C and Supplemental Figure 13) and suggests that CLL cells utilize pAktS473 to survive the BTK/BCR signaling inhibition.